{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T23:35:50Z","timestamp":1773963350548,"version":"3.50.1"},"reference-count":44,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["5 \\u00D7 1000"],"award-info":[{"award-number":["5 \\u00D7 1000"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003197","name":"Italian Medicines Agency","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003197","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Italian Association for Cancer Research","doi-asserted-by":"publisher","award":["IG 2017\/20760"],"award-info":[{"award-number":["IG 2017\/20760"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.esmoop.2025.105924","type":"journal-article","created":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T19:16:07Z","timestamp":1767726967000},"page":"105924","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Validation of PREDICT tool v2.2 in patients with early-stage breast cancer enrolled in the GIM and MIG trials"],"prefix":"10.1016","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5403-0916","authenticated-orcid":false,"given":"R.","family":"Borea","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9566-4579","authenticated-orcid":false,"given":"E.","family":"Blondeaux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Carmisciano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3818-0364","authenticated-orcid":false,"given":"L.","family":"Arecco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Perachino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4518-2827","authenticated-orcid":false,"given":"F.","family":"Poggio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Ruelle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Luelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9009-1572","authenticated-orcid":false,"given":"M.","family":"de Laurentiis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Arpino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0573-4938","authenticated-orcid":false,"given":"F.","family":"Puglisi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Fabi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Gori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Fregatti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1797-5296","authenticated-orcid":false,"given":"M.","family":"Lambertini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2217-4047","authenticated-orcid":false,"given":"L.","family":"Boni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9546-5841","authenticated-orcid":false,"given":"L.","family":"Del Mastro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.esmoop.2025.105924_bib1","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"10.1016\/j.esmoop.2025.105924_bib2","first-page":"409","article-title":"Cancer treatment and survivorship statistics, 2022","volume":"72","author":"Miller","year":"2022","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105924_bib3","doi-asserted-by":"crossref","DOI":"10.1186\/bcr2464","article-title":"PREDICT: a new UK prognostic model that predicts survival following surgery for invasive breast cancer","volume":"12","author":"Wishart","year":"2010","journal-title":"Breast Cancer Res"},{"issue":"5","key":"10.1016\/j.esmoop.2025.105924_bib4","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1038\/bjc.2012.338","article-title":"PREDICT Plus: development and validation of a prognostic model for early breast cancer that includes HER2","volume":"107","author":"Wishart","year":"2012","journal-title":"Br J Cancer"},{"key":"10.1016\/j.esmoop.2025.105924_bib5","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1186\/1471-2407-14-908","article-title":"Inclusion of KI67 significantly improves performance of the PREDICT prognostication and prediction model for early breast cancer","volume":"14","author":"Wishart","year":"2014","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105924_bib6","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s13058-017-0852-3","article-title":"An updated PREDICT breast cancer prognostication and treatment benefit prediction model with independent validation","volume":"19","author":"Candido Dos Reis","year":"2017","journal-title":"Breast Cancer Res"},{"issue":"6","key":"10.1016\/j.esmoop.2025.105924_bib7","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.3892\/ol.2014.2589","article-title":"Effect of PREDICT on chemotherapy\/trastuzumab recommendations in HER2-positive patients with early-stage breast cancer","volume":"8","author":"Down","year":"2014","journal-title":"Oncol Lett"},{"key":"10.1016\/j.esmoop.2025.105924_bib8","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.ejca.2022.06.011","article-title":"Incorporating progesterone receptor expression into the PREDICT breast prognostic model","volume":"173","author":"Grootes","year":"2022","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105924_bib9","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41523-024-00612-y","article-title":"An updated PREDICT breast cancer prognostic model including the benefits and harms of radiotherapy","volume":"10","author":"Grootes","year":"2024","journal-title":"NPJ Breast Cancer"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105924_bib10","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/s41523-022-00452-8","article-title":"PREDICT underestimates survival of patients with HER2-positive early-stage breast cancer","volume":"8","author":"Agostinetto","year":"2022","journal-title":"NPJ Breast Cancer"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105924_bib11","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41523-023-00546-x","article-title":"PREDICT validity for prognosis of breast cancer patients with pathogenic BRCA1\/2 variants","volume":"9","author":"Muranen","year":"2023","journal-title":"NPJ Breast Cancer"},{"issue":"10","key":"10.1016\/j.esmoop.2025.105924_bib12","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.6004\/jnccn.2023.7048","article-title":"Validation of the PREDICT prognostication tool in US patients with breast cancer","volume":"21","author":"Stabellini","year":"2023","journal-title":"J Natl Compr Cancer Netw"},{"issue":"11","key":"10.1016\/j.esmoop.2025.105924_bib13","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1038\/s41416-020-0816-8","article-title":"Dose-dense adjuvant chemotherapy in early breast cancer patients: 15-year results of the phase 3 Mammella InterGruppo (MIG)-1 study","volume":"122","author":"Blondeaux","year":"2020","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105924_bib14","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s10549-015-3655-1","article-title":"5-Fluorouracil, epirubicin and cyclophosphamide versus epirubicin and paclitaxel in node-positive early breast cancer: a phase-III randomized GONO-MIG5 trial","volume":"155","author":"Del Mastro","year":"2016","journal-title":"Breast Cancer Res Treat"},{"issue":"12","key":"10.1016\/j.esmoop.2025.105924_bib15","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/S1470-2045(22)00632-5","article-title":"Fluorouracil and dose-dense adjuvant chemotherapy in patients with early-stage breast cancer (GIM2): end-of-study results from a randomised, phase 3 trial","volume":"23","author":"Del Mastro","year":"2022","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105924_bib16","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/S1470-2045(18)30116-5","article-title":"Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial","volume":"19","author":"De Placido","year":"2018","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105924_bib17","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1093\/jnci\/djab213","article-title":"Long-term outcomes with pharmacological ovarian suppression during chemotherapy in premenopausal early breast cancer patients","volume":"114","author":"Lambertini","year":"2022","journal-title":"J Natl Cancer Inst"},{"issue":"24","key":"10.1016\/j.esmoop.2025.105924_bib19","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1200\/JCO.20.03613","article-title":"Updated Standardized Definitions for Efficacy End Points (STEEP) in adjuvant breast cancer clinical trials: STEEP version 2.0","volume":"39","author":"Tolaney","year":"2021","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2025.105924_bib20","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1038\/bjc.2015.57","article-title":"An evaluation of the prognostic model PREDICT using the POSH cohort of women aged \u226440 years at breast cancer diagnosis","volume":"112","author":"POSH Steering Group","year":"2015","journal-title":"Br J Cancer"},{"issue":"8","key":"10.1016\/j.esmoop.2025.105924_bib21","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000000593","article-title":"The predictive accuracy of PREDICT: a personalized decision-making tool for Southeast Asian women with breast cancer","volume":"94","author":"Wong","year":"2015","journal-title":"Medicine"},{"issue":"5","key":"10.1016\/j.esmoop.2025.105924_bib22","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1111\/jep.13084","article-title":"External validation of the PREDICT tool in Spanish women with breast cancer participating in population-based screening programmes","volume":"25","author":"Aguirre","year":"2019","journal-title":"J Eval Clin Pract"},{"key":"10.1016\/j.esmoop.2025.105924_bib23","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.ejca.2017.09.031","article-title":"Validation of the online prediction tool PREDICT v. 2.0 in the Dutch breast cancer population","volume":"86","author":"Van Maaren","year":"2017","journal-title":"Eur J Cancer"},{"issue":"7","key":"10.1016\/j.esmoop.2025.105924_bib24","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1038\/s41416-018-0256-x","article-title":"Independent validation of the PREDICT breast cancer prognosis prediction tool in 45,789 patients using Scottish Cancer Registry data","volume":"119","author":"Gray","year":"2018","journal-title":"Br J Cancer"},{"key":"10.1016\/j.esmoop.2025.105924_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.113401","article-title":"External validation and clinical utility assessment of PREDICT breast cancer prognostic model in young, systemic treatment-na\u00efve women with node-negative breast cancer","volume":"195","author":"Wang","year":"2023","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105924_bib26","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/bjc.2015.466","article-title":"Validity of the online PREDICT tool in older patients with breast cancer: a population-based study","volume":"114","author":"De Glas","year":"2016","journal-title":"Br J Cancer"},{"issue":"5","key":"10.1016\/j.esmoop.2025.105924_bib27","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1002\/cam4.3713","article-title":"Validity of the prognostication tool PREDICT version 2.2 in Japanese breast cancer patients","volume":"10","author":"Zaguirre","year":"2021","journal-title":"Cancer Med"},{"issue":"10461","key":"10.1016\/j.esmoop.2025.105924_bib28","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/S0140-6736(24)01745-8","article-title":"Reductions in recurrence in women with early breast cancer entering clinical trials between 1990 and 2009: a pooled analysis of 155 746 women in 151 trials","volume":"404","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.esmoop.2025.105924_bib29","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/7146172","article-title":"Neoadjuvant trastuzumab and pertuzumab for early HER2-positive breast cancer: a real world experience","volume":"2022","author":"Hall","year":"2022","journal-title":"Breast J"},{"issue":"7","key":"10.1016\/j.esmoop.2025.105924_bib30","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa1814017","article-title":"Trastuzumab emtansine for residual invasive HER2-positive breast cancer","volume":"380","author":"Von Minckwitz","year":"2019","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105924_bib31","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s10549-014-2917-7","article-title":"Impact of comorbidity on outcome of older breast cancer patients: a FOCUS cohort study","volume":"145","author":"Kiderlen","year":"2014","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.esmoop.2025.105924_bib32","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ejca.2017.03.015","article-title":"Accuracy of the online prognostication tools PREDICT and Adjuvant! for early-stage breast cancer patients younger than 50 years","volume":"78","author":"Engelhardt","year":"2017","journal-title":"Eur J Cancer"},{"issue":"8","key":"10.1016\/j.esmoop.2025.105924_bib33","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/nrclinonc.2012.102","article-title":"Breast cancer in young women","volume":"9","author":"Narod","year":"2012","journal-title":"Nat Rev Clin Oncol"},{"issue":"9","key":"10.1016\/j.esmoop.2025.105924_bib34","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.annonc.2024.06.009","article-title":"Impact of hormone receptor status and tumor subtypes of breast cancer in young BRCA carriers","volume":"35","author":"Arecco","year":"2024","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.esmoop.2025.105924_bib35","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/j.annonc.2022.09.159","article-title":"Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1\/2 and high-risk, early breast cancer","volume":"33","author":"Geyer","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2025.105924_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.101931","volume":"59","author":"Lambertini","year":"2023","journal-title":"EClinicalMedicine"},{"issue":"10","key":"10.1016\/j.esmoop.2025.105924_bib37","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1093\/annonc\/mdu042","article-title":"Body mass index and survival in women with breast cancer\u2014systematic literature review and meta-analysis of 82 follow-up studies","volume":"25","author":"Chan","year":"2014","journal-title":"Ann Oncol"},{"issue":"suppl 12","key":"10.1016\/j.esmoop.2025.105924_bib38","first-page":"G2","article-title":"Overweight, obesity and prognosis in 206,904 women in the Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG) database","volume":"31","author":"Pan","year":"2025","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.esmoop.2025.105924_bib39","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1038\/s41416-024-02833-1","article-title":"Implications of obesity and insulin resistance for the treatment of oestrogen receptor-positive breast cancer","volume":"131","author":"Javed","year":"2024","journal-title":"Br J Cancer"},{"key":"10.1016\/j.esmoop.2025.105924_bib40","series-title":"NCCN Clinical Practice Guidelines in Oncology: Breast Cancer version 5.2025","year":"2025"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105924_bib41","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.annonc.2023.11.016","article-title":"Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"35","author":"Loibl","year":"2024","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2025.105924_bib42","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/S1470-2045(16)00163-7","article-title":"5-Year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial","volume":"17","author":"Gianni","year":"2016","journal-title":"Lancet Oncol"},{"issue":"34","key":"10.1016\/j.esmoop.2025.105924_bib43","doi-asserted-by":"crossref","first-page":"3987","DOI":"10.1200\/JCO.20.02514","article-title":"Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast cancer (monarchE)","volume":"38","author":"Johnston","year":"2020","journal-title":"J Clin Oncol"},{"issue":"25","key":"10.1016\/j.esmoop.2025.105924_bib44","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1056\/NEJMoa2105215","article-title":"Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer","volume":"384","author":"Tutt","year":"2021","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.esmoop.2025.105924_bib45","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1056\/NEJMoa2305488","article-title":"Ribociclib plus endocrine therapy in early breast cancer","volume":"390","author":"Slamon","year":"2024","journal-title":"N Engl J Med"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925017946?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925017946?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T20:54:30Z","timestamp":1773953670000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702925017946"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S2059702925017946"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.105924","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Validation of PREDICT tool v2.2 in patients with early-stage breast cancer enrolled in the GIM and MIG trials","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.105924","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"105924"}}